Alex Slandzicki, MD
Family Medicine · Franklin, TNNPI 1144264458
Payments from drug & device makers
What this record shows
22 manufacturers reported payments, led by Novo Nordisk at 48.5% of the total. Reporting peaked in 2022 at $1,859 and has fallen 97.2% since, to $53 in 2024.
Across 112 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- GSK$451
- Amgen$278
- AstraZeneca$265
- Acadia Pharmaceuticals Inc$134
- Johnson & Johnson$122
- plus $715 from 16 others
Across 41 payments — averaging $3002.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adamis Pharmaceuticals Corporation$79K
- GSK$27K
- Verona Pharma, Inc.$17K
What the payments were for
- Consulting fees$1,62042%
- Food & beverage$2,19358%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $1,848 |
| GSK | 23 | $451 |
| Amgen | 13 | $278 |
| AstraZeneca | 10 | $265 |
| Acadia Pharmaceuticals Inc | 2 | $134 |
| Johnson & Johnson(2 entities) | 7 | $122 |
| AbbVie(2 entities) | 7 | $121 |
| Organogenesis Inc. | 1 | $79 |
| Lilly USA, LLC | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Merck | 5 | $59 |
| UCB, Inc. | 1 | $53 |
| Pfizer | 3 | $49 |
| Boehringer Ingelheim | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,813 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 524 | $135,982 |
| MyrbetriqMirabegron | 198 | $31,125 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 48 | $14,496 |
| JanuviaSitagliptin Phosphate | 45 | $11,046 |
| XareltoRivaroxaban | 56 | $8,575 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $8,144 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 99 | $7,471 |
| JardianceEmpagliflozin | 12 | $7,049 |
| LinzessLinaclotide | 12 | $6,986 |
| Atorvastatin Calcium | 647 | $6,538 |
| Metoprolol Succinate | 451 | $5,779 |
| LumiganBimatoprost | 19 | $5,115 |
| EntrestoSacubitril/Valsartan | 17 | $5,066 |
| Memantine Hcl | 125 | $4,441 |
| Levothyroxine Sodium | 343 | $3,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $49 | $150,478572 claims |
| AbbVieLinzess, Lumigan | $121 | $12,10131 claims |
| MerckJanuvia | $59 | $11,04645 claims |
| Johnson & JohnsonXarelto | $122 | $8,57556 claims |
| Boehringer IngelheimJardiance | $43 | $7,04912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Franklin
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.